Stephen T. Magill
Has grant
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Stephen T. Magill is an Assistant Professor at Northwestern University in the United States. His research primarily focuses on the evolving classification of meningiomas and the prognostic factors affecting patients with pineoblastoma. Through his recent articles, he integrates molecular discoveries to enhance patient care and analyzes trends in post-surgical outcomes for individuals with brain tumors.
Recent Grants
Grant: Close
Development of a molecular diagnostic and prognostic signature for meningioma
Open Date: 2017-07-01
Close Date: 2018-06-30
Articles (22)
Meningiomas are the most common primary brain tumors and, despite their benign reputation, often behave aggressively. Meningiomas are morphologically heterogeneous, yet the full significance of their histologic diversity is unclear. This is in large part because many features are not readily quantifiable by traditional observer-based light microscopy. Molecular testing improves prognostic stratification, but is not universally accessible. We therefore sought to determine whether an artificial intelligence (AI)-trained program could predict specific genomic and epigenomic patterns in meningiomas, and whether it could extract more prognostic information out of standard hematoxylin and eosin (H&E) histopathology than the current WHO classification. To do this, we developed Morphologic Set Enrichment (MSE), an interpretable computational pathology framework that quantifies statistical enrichment of morphologic patterns, cells, and tissue architecture from H&E whole-slide images. The MSE meningioma histology program was able to accurately predict DNA methylation subtypes and concurrent chromosome 1p/22q losses, in the process identifying specific morphologic patterns associated with key genomic and epigenomic alterations. It also added prognostic value independent of standard clinical and pathological variables. These results demonstrate that AI-based quantitative morphologic profiling can capture clinically and biologically relevant information that redefines risk stratification for meningiomas, incorporating histological information not included in existing grading schemes.
Year:
2026
Brain tumor-related epilepsy (BTRE) is a common and debilitating symptom of central nervous system (CNS) tumors. The epileptogenic zone, defined as cortex responsible for seizure generation, is located at the peritumoral region for most tumors, and lower-grade intrinsic brain tumors have the highest seizure incidence. Surgery is often the most effective treatment for the reduction in seizures in BTRE. However, surgical decisions have historically often been made exclusively for oncologic reasons, with less emphasis on seizure control. Surgical approaches for all tumor types are reviewed, highlighting relevant risk factors. Adjunctive tools during surgery, such as intraoperative electrocorticography (ECoG), may help identify and remove surrounding brain areas which are epileptogenic. Minimally invasive surgery is also gaining traction, given its utility in treating seizures deep-seated tumors. This review explores epileptogenic brain tumors, surgery for BTRE, and emerging strategies to better achieve seizure control.
Year:
2025
Meningioma classification and treatment have evolved over the past eight decades. Since Bailey, Cushing, and Eisenhart’s description of meningiomas in the 1920s and 1930s, there have been continual advances in clinical stratification by histopathology, radiography and, most recently, molecular profiling, to improve prognostication and predict response to therapy. Precise and accurate classification is essential to optimizing management for patients with meningioma, which involves surveillance imaging, surgery, primary or adjuvant radiotherapy, and consideration for clinical trials. Currently, the World Health Organization (WHO) grade, extent of resection (EOR), and patient characteristics are used to guide management. While these have demonstrated reliability, a substantial number of seemingly benign lesions recur, suggesting opportunities for improvement of risk stratification. Furthermore, the role of adjuvant radiotherapy for grade 1 and 2 meningioma remains controversial. Over the last decade, numerous studies investigating the molecular drivers of clinical aggressiveness have been reported, with the identification of molecular markers that carry clinical implications as well as biomarkers of radiotherapy response. Here, we review the historical context of current practices, highlight recent molecular discoveries, and discuss the challenges of translating these findings into clinical practice.
Year:
2024
Supplementary Fig. 6. WHO grade 3 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 is expressed in and out of the perivascular niche, and colocalizes with mural cells in the perivascular niche, in meningiomas with WHO grade 3 histology. SF numbers indicate individual meningiomas. Representative of n=10 WHO grade 3 meningiomas. WHO grade defined using histological criteria. Scale bars, 10µm.
Year:
2024
Supplementary Table S1. Cell cluster marker genes from single-cell RNA sequencing of human meningiomas with loss of chromosome 22q. Supplementary Table S2. Cell cluster marker genes from single-cell RNA sequencing of dog meningiomas. Supplementary Table S3. RNA sequencing differential expression analyses across recurrent versus primary human meningiomas. Supplementary Table S4. Antibodies for multiplexed sequential immunofluorescence. Supplementary Table S5. Cell cluster marker genes from single-cell RNA sequencing of human cells from meningioma xenografts. Supplementary Table S6. Cell cluster marker genes from single-cell RNA sequencing of mouse cells from meningioma xenografts.
Year:
2024
Supplementary Fig. 5. WHO grade 2 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 expression is primarily restricted to the perivascular niche and colocalizes with mural cells in meningiomas with WHO grade 2 histology. SF numbers indicate individual meningiomas. WHO grade defined using histological criteria. Representative of n=10 WHO grade 2 meningiomas. Scale bars, 10µm.
Year:
2024
Supplementary Fig. 4. WHO grade 1 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 expression is restricted to the perivascular niche and colocalizes with mural cells in meningiomas with WHO grade 1 histology. SF numbers indicate individual meningiomas. WHO grade defined using histological criteria. Representative of n=10 WHO grade 1 meningiomas. Scale bars, 10µm.
Year:
2024
Supplementary Fig. 13. Analysis of human and mouse cell types from single-cell RNA sequencing of meningioma xenografts. A, Feature plots showing differentially expressed genes across UMAP clusters from CH-157MN meningioma xenograft human cells analyzed using single-cell RNA sequencing. See also Supplementary Table 5. B, Meningioma xenograft human single-cell cluster changes across experimental conditions and biological replicates. Student’s t -tests. C, Single-cell RNA sequencing UMAP of 34,902 meningioma xenograft mouse cell transcriptomes showing microenvironment cell types. D, Feature plots showing differentially expressed genes across UMAP clusters from meningioma xenograft mouse cells analyzed using single-cell RNA sequencing. E, Meningioma xenograft mouse single-cell cluster changes across experimental conditions and biological replicates. See also Supplementary Table 6. Student’s t tests.
Year:
2024
Supplementary Fig. 11. Ptgds is expressed throughout the meninges. Confocal microscopy of whole mount mouse convexity meningeal samples at P7, P30, or P90 after recombination of the ROSAmT/mG allele using Ptgds-Cre shows PTGDS cells are diffusely expressed throughout perivascular and non-perivascular meningeal cells. DAPI marks DNA. Representative of n=3 biological replicates per timepoint. Scale bar, 100µm.
Year:
2024
Supplementary Fig. 9. WHO grade 3 meningioma immunofluorescence microscopy for NOTCH3 and the endothelial cell marker VWF. NOTCH3 is expressed in and out of the perivascular niche, and is adjacent to endothelial cells in the perivascular niche, in meningiomas with WHO grade 3 histology. SF numbers indicate individual meningiomas. Representative of n=10 WHO grade 3 meningiomas. WHO grade defined using histological criteria. Scale bars, 10µm.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (20)
Mark Youngblood
Assistant Professor
Northwestern Memorial Hospital
Aparna Bhaduri
Assistant Professor
University of California, Los Angeles
Brisa Palikuqi
Assistant Professor
Yale University
Craig Horbinski
Northwestern University
Kapil Gururangan
Assistant Professor of Neurology
Northwestern University
Peter J. Dickinson
-
James Chandler
Vice-Chair
Northwestern University
Ophir Klein
Cedars-Sinai Medical Center
Rimas V Lukas
Northwestern University
Alan Ashworth
University of California, San Francisco
Shawn L. Hervey‐Jumper
Professor
University of California, San Francisco
Amy B. Heimberger
Professor
Northwestern University
Calixto-Hope G Lucas
Johns Hopkins University School of Medicine
Christine M. Toedebusch
University of California
Arie Perry
University of California, San Francisco
Jared Ahrendsen
Assistant Professor
Northwestern University Feinberg School of Medicine
Lee A D Cooper
Associate Professor, Director, Computational Pathology
Northwestern University
David R Raleigh
University of California, San Francisco
Jessica Templer
Northwestern University
Joanna J. Phillips
Profesor
University of California, San Francisco
Make your next move.
Prepare your application
Review drafts before you send them.